CN109985008A - A kind of astaxanthin solid self-microemulsion and preparation method thereof - Google Patents
A kind of astaxanthin solid self-microemulsion and preparation method thereof Download PDFInfo
- Publication number
- CN109985008A CN109985008A CN201910357578.5A CN201910357578A CN109985008A CN 109985008 A CN109985008 A CN 109985008A CN 201910357578 A CN201910357578 A CN 201910357578A CN 109985008 A CN109985008 A CN 109985008A
- Authority
- CN
- China
- Prior art keywords
- astaxanthin
- microemulsion
- solid self
- solid
- self
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
技术领域technical field
本发明涉及一种虾青素固体自微乳及其制备方法,属于功能食品制备技术中的载体系统技术领域。The invention relates to an astaxanthin solid self-microemulsion and a preparation method thereof, belonging to the technical field of carrier systems in the preparation technology of functional food.
背景技术Background technique
虾青素是一种非维生素A 源的脂溶性酮式类胡萝卜素,存在形态主要为游离态和酯化态,其分子结构中特殊的共轭双键和羟基是它相较维生素E和β-胡萝卜素拥有更强的抗氧化活性,它是迄今为止自然界中最强的天然抗氧化剂。有研究表明,虾青素具有多种生理活性,如减缓衰老、抗肿瘤、预防心脑血管疾病、治疗糖尿病、消炎、改善运动机能等。虾青素能够有效清除体内自由基,同时促进抗体生成,提高动物免疫力,不仅可以抗炎防癌,防止紫外线辐射,还可以预防心血管、神经系统等方面的疾病,在食品、保健品、医药行业均有可观的实用价值和应用前景。Astaxanthin is a non-vitamin A source of fat-soluble keto-carotenoid. It exists in free and esterified forms. The special conjugated double bonds and hydroxyl groups in its molecular structure make it comparable to vitamin E and β- Carotene has stronger antioxidant activity, it is by far the strongest natural antioxidant in nature. Studies have shown that astaxanthin has a variety of physiological activities, such as slowing down aging, anti-tumor, preventing cardiovascular and cerebrovascular diseases, treating diabetes, anti-inflammatory, and improving motor function. Astaxanthin can effectively remove free radicals in the body, at the same time promote the production of antibodies and improve animal immunity. The pharmaceutical industry has considerable practical value and application prospects.
虾青素是目前发现唯一能穿透血-脑、血-视网膜屏障的类胡萝卜素,对中枢神经系统和大脑功能可产生积极的影响。因此若将虾青素作为膳食功能因子添加到食品当中,对改善人体健康将具有切实的意义。但是虾青素本身光稳定性差,生物利用度低,限制了其在保健品、医药领域方面的应用。Astaxanthin is the only carotenoid found so far that can penetrate the blood-brain and blood-retina barriers, and can have a positive impact on the central nervous system and brain function. Therefore, if astaxanthin is added to food as a dietary functional factor, it will have practical significance for improving human health. However, astaxanthin itself has poor photostability and low bioavailability, which limit its application in the fields of health care products and medicine.
脂质制剂载药系统在1981年时以简单的油溶液形式进入到药学领域。随后,脂质制剂载药系统在市面上的产品多以自乳化制剂为主,自乳化载药系统可以作为一种有效的手段为了能提高难溶药物的生物利用度,自乳化配方突显了脂质在提高亲脂药物口服吸收方面的重要性。但是脂质制剂在市面上存在剂型单一少,应用范围窄的应用瓶颈Lipid drug delivery systems entered the field of pharmacy in 1981 as simple oil solutions. Subsequently, most products on the market of lipid preparation drug-carrying systems are self-emulsifying preparations. Self-emulsifying drug-carrying systems can be used as an effective means to improve the bioavailability of poorly soluble drugs. The importance of quality in enhancing oral absorption of lipophilic drugs. However, there are application bottlenecks in the market of lipid preparations, which have a single dosage form and a narrow application range.
为了弥补脂质制剂面临的应用缺陷,固体脂质载药系统(solid-state-lipid-baseddrug delivery systems,s-LBDDS)近年来已经引起了科研工作者的研究兴趣。固体脂质制剂的制备过程为:利用干燥技术将液体脂质制剂吸附到化学性质稳定的固体载体中,从而制备得到固体剂型的样品(如散粉、颗粒和微丸等)。固体制剂的选择应着眼于其具有优秀的脂质吸附能力、良好的水溶性和固体特性。In order to make up for the application defects faced by lipid formulations, solid-state-lipid-based drug delivery systems (s-LBDDS) have attracted the research interest of researchers in recent years. The preparation process of solid lipid preparations is as follows: using drying technology to adsorb liquid lipid preparations into chemically stable solid carriers, so as to prepare samples of solid dosage forms (such as loose powders, granules and pellets, etc.). The selection of solid formulations should focus on their excellent lipid adsorption capacity, good water solubility and solid properties.
固体脂质制剂载药系统结合了脂质制剂配方和固体剂型的双重优势:1)减少了样品的体积(常规的乳液或混悬液配方中至少含有50%量的水分,固体化后样品的体积可能只有一粒片剂或胶囊的规格);2)口服用量可以精准确定;3)相比液体剂型,固体剂型更便于病人的口服治疗过程;4)固体脂质制剂配方中不含或含有少量水分,体积小,长期存储的物理化学稳定性高,易于长期运输存贮。The solid lipid preparation drug delivery system combines the dual advantages of lipid preparation formulations and solid dosage forms: 1) The volume of the sample is reduced (conventional emulsion or suspension formulations contain at least 50% moisture, and the sample volume after solidification is at least 50%). The volume may only be the size of a tablet or capsule); 2) The oral dosage can be accurately determined; 3) Compared with the liquid dosage form, the solid dosage form is more convenient for the patient's oral treatment process; 4) The solid lipid formulation does not contain or contains A small amount of water, small size, high physical and chemical stability for long-term storage, easy to transport and store for a long time.
发明内容SUMMARY OF THE INVENTION
本发明针对现有技术中存在的不足,提供了一种虾青素固体自微乳及其制备方法,解决现有技术中虾青素的溶解性差、负载量低及口服生物利用度低等缺点和不足之处。Aiming at the deficiencies in the prior art, the present invention provides an astaxanthin solid self-microemulsion and a preparation method thereof, and solves the disadvantages of the prior art such as poor solubility, low loading and low oral bioavailability of astaxanthin. and deficiencies.
为实现上述目的,本发明采用的技术方案如下:For achieving the above object, the technical scheme adopted in the present invention is as follows:
一种虾青素固体自微乳,由如下质量百分比的组分构成:An astaxanthin solid self-microemulsion is composed of the following components by mass percentage:
虾青素 1-5%Astaxanthin 1-5%
油脂 10-20%Grease 10-20%
乳化剂 20-30%Emulsifier 20-30%
助乳化剂 10-20%Co-emulsifier 10-20%
固体吸附剂 10-50%。 Solid sorbent 10-50%.
作为本发明的一种改进,所述油脂为椰子油、玉米油、辛癸酸甘油三酯、葡萄籽油、月见草油中任意一种或以上的组合。As an improvement of the present invention, the oil is any one or a combination of coconut oil, corn oil, caprylic triglyceride, grape seed oil, and evening primrose oil.
作为本发明的一种改进,所述乳化剂为吐温60、吐温80、吐温20、十聚甘油单月桂酸酯、辛酸/癸酸聚乙二醇甘油酯、聚氧乙稀(40)硬脂酸、鲸蜡硬脂醇和山梨坦橄榄油酸酯、山梨坦橄榄油酸酯、鲸蜡硬脂醇聚醚-6橄榄油酸酯中任意一种或以上的组合。As an improvement of the present invention, the emulsifier is Tween 60, Tween 80, Tween 20, ten polyglycerol monolaurate, caprylic/capric acid polyethylene glycol glyceride, polyoxyethylene (40 ) any one or a combination of stearic acid, cetearyl alcohol and sorbitan oleate, sorbitan oleate, and cetearyl oleate-6 oleate.
作为本发明的一种改进,所述助乳化剂为聚甘油蓖麻醇酯、鲸蜡基聚乙二醇/聚丙二醇-10/1二甲基硅氧烷、聚乙二醇-30二聚羟基硬脂酸酯、聚乙二醇-400中任意一种或以上的组合。As an improvement of the present invention, the co-emulsifier is polyglycerol ricinole ester, cetyl polyethylene glycol/polypropylene glycol-10/1 dimethylsiloxane, polyethylene glycol-30 dimer Any one or a combination of hydroxystearate and polyethylene glycol-400.
作为本发明的一种改进,所述固体吸附剂为无水磷酸氢钙、硅酸镁铝、二氧化硅、阿拉伯树胶、柠檬酸异丙酯中的任意一种。As an improvement of the present invention, the solid adsorbent is any one of anhydrous calcium hydrogen phosphate, magnesium aluminum silicate, silicon dioxide, gum arabic, and isopropyl citrate.
作为本发明的一种改进,所述虾青素固体自微乳的粒径范围为50-150nm。As an improvement of the present invention, the particle size range of the astaxanthin solid self-microemulsion is 50-150 nm.
作为本发明的一种改进,所述虾青素固体自微乳的制备方法,包括以下步骤:As a kind of improvement of the present invention, the preparation method of described astaxanthin solid self-microemulsion, comprises the following steps:
(1)按重量百分比准备以下组分:虾青素1-5%、油脂10-20%、乳化剂20-30%、助乳化剂10-20%、固体吸附剂10-50%;(1) Prepare the following components by weight percentage: astaxanthin 1-5%, oil 10-20%, emulsifier 20-30%, co-emulsifier 10-20%, solid adsorbent 10-50%;
(2)将虾青素、油脂混合后于室温下搅拌至溶解,形成油相体系;(2) Mix astaxanthin and oil and stir at room temperature until dissolved to form an oil phase system;
(3)将乳化剂、助乳化剂在50-70℃恒温水浴中搅拌后,加入至油相体系中混合,得到虾青素液态自微乳;(3) After stirring the emulsifier and co-emulsifier in a constant temperature water bath at 50-70°C, add them to the oil phase system and mix to obtain astaxanthin liquid self-microemulsion;
(4)冷却至常温后,向虾青素液态自微乳中加入固体吸附剂,在常温下进行物理混合吸附,得到虾青素固体自微乳。(4) After cooling to normal temperature, adding a solid adsorbent to the astaxanthin liquid self-microemulsion, and performing physical mixing and adsorption at normal temperature to obtain the astaxanthin solid self-microemulsion.
作为本发明的一种改进,一种虾青素固体自微乳在制备功能食品中的应用。As an improvement of the present invention, an application of astaxanthin solid self-microemulsion in preparing functional food.
本发明中所述载体负载为虾青素,其具有抗氧化、抗炎的功效,虾青素固体自微乳的制备方法为物理吸附法,液体自微乳与二氧化硅进行物理混合吸附,并在常温下制备得到虾青素固体自微乳。该载体具有良好的稳定性和水溶性,制备方法简单可控,重复性好,可以应用于含有虾青素的功能食品的制备中。In the present invention, the carrier load is astaxanthin, which has antioxidative and anti-inflammatory effects. The preparation method of astaxanthin solid self-microemulsion is a physical adsorption method, and the liquid self-microemulsion and silicon dioxide are physically mixed and adsorbed. And the astaxanthin solid self-microemulsion is prepared at normal temperature. The carrier has good stability and water solubility, the preparation method is simple and controllable, and the repeatability is good, and can be applied to the preparation of functional foods containing astaxanthin.
由于采用了以上技术,本发明较现有技术相比,具有的有益效果如下:Owing to having adopted the above technology, compared with the prior art, the present invention has the following beneficial effects:
(1)本发明的虾青素固体自微乳体系具有良好的稳定性;(1) The astaxanthin solid self-microemulsion system of the present invention has good stability;
(2)提高了难溶于水的虾青素的溶解性,从而提高其生物利用度;(2) Improve the solubility of insoluble astaxanthin, thereby improving its bioavailability;
(3)配方中各组分具有很高的安全性,对机体无刺激性,无毒性,可作为中间体类型与食品配方复配使用,配伍性佳,可广泛用于食品及保健品领域;(3) Each component in the formula has high safety, is non-irritating to the body, non-toxic, can be used as an intermediate type in combination with food formula, has good compatibility, and can be widely used in the field of food and health products;
(4)该制备方法简单可控,重复性好。(4) The preparation method is simple and controllable and has good repeatability.
附图说明Description of drawings
图1为本发明虾青素固体自微乳体系的制备方法流程图。Fig. 1 is the flow chart of the preparation method of the astaxanthin solid self-microemulsion system of the present invention.
具体实施方式Detailed ways
以下结合实施例对本发明作进一步描述。这些实施例是用于说明本发明而不限于限制本发明的范围。实施例中采用的实施条件可以根据具体厂家的条件做进一步调整。The present invention will be further described below in conjunction with the embodiments. These examples are intended to illustrate the invention and not to limit the scope of the invention. The implementation conditions adopted in the embodiments can be further adjusted according to the conditions of specific manufacturers.
实施例1:Example 1:
称取0.2 g虾青素以及2.0g玉米油,将虾青素、玉米油混合后于室温下搅拌至大部分虾青素溶解到玉米油中,形成体系的油相;称取3g吐温60和2.0g聚乙二醇-400,将吐温60和聚乙二醇-400于50℃恒温水浴中搅拌加入油相中,使其充分混合形成均一相,得到虾青素液态自微乳;冷却至常温后,向虾青素液态自微乳中加入5g的二氧化硅作为固体吸附剂,在常温下进行物理混合吸附,使其混合均匀,最终得到虾青素固体自微乳。Weigh 0.2 g of astaxanthin and 2.0 g of corn oil, mix astaxanthin and corn oil and stir at room temperature until most of the astaxanthin is dissolved in the corn oil to form the oil phase of the system; weigh 3 g of Tween 60 and 2.0 g of polyethylene glycol-400, Tween 60 and polyethylene glycol-400 were stirred in a 50°C constant temperature water bath and added to the oil phase, so that they were fully mixed to form a homogeneous phase to obtain astaxanthin liquid self-microemulsion; After cooling to normal temperature, 5 g of silicon dioxide was added to the astaxanthin liquid self-microemulsion as a solid adsorbent, and physical mixing and adsorption was carried out at normal temperature to make the mixture uniform, and finally the astaxanthin solid self-microemulsion was obtained.
将1.0 g虾青素固体自微乳体系加入到100g去离子水中,均匀分散后,利用粒度仪测得虾青素固体自微乳体系水分散后平均粒径为121.2±2.8nm,并25℃室温放置1个月后其平均粒径为130.7±3.0nm,其粒径变化无明显差异,显示其稳定性良好。1.0 g of astaxanthin solid self-microemulsion system was added to 100g of deionized water, and after uniform dispersion, the average particle size of astaxanthin solid self-microemulsion system after water dispersion was measured by particle size analyzer was 121.2 ± 2.8nm, and 25 ℃. After being placed at room temperature for 1 month, the average particle size was 130.7±3.0 nm, and there was no significant difference in the particle size change, indicating good stability.
实施例2:Example 2:
称取2 g虾青素以及18.5g椰子油,将虾青素、椰子油混合后于室温下搅拌至大部分虾青素溶解到椰子油中,形成体系的油相;称取30g吐温20和25g聚甘油蓖麻醇酯,将吐温20和聚甘油蓖麻醇酯于50℃恒温水浴中搅拌加入油相中,使其充分混合形成均一相,得到虾青素液态自微乳;冷却至常温后,向虾青素液态自微乳中加入44 g的硅酸镁铝作为固体吸附剂,在常温下进行物理混合吸附,使其混合均匀,最终得到虾青素固体自微乳。Weigh 2 g of astaxanthin and 18.5 g of coconut oil, mix astaxanthin and coconut oil and stir at room temperature until most of the astaxanthin is dissolved in the coconut oil to form the oil phase of the system; weigh 30 g of Tween 20 and 25g of polyglycerol ricinoleate, Tween 20 and polyglycerol ricinoleate are stirred into the oil phase in a 50° C. constant temperature water bath, and fully mixed to form a homogeneous phase to obtain astaxanthin liquid self-microemulsion; cooling; After reaching room temperature, 44 g of magnesium aluminum silicate was added to the astaxanthin liquid self-microemulsion as a solid adsorbent, and physical mixing and adsorption was carried out at room temperature to make it evenly mixed, and finally astaxanthin solid self-microemulsion was obtained.
将1.0g虾青素固体自微乳体系加入到100g去离子水中,均匀分散后,利用粒度仪测得虾青素固体自微乳体系水分散后平均粒径为137.5±3.3nm,并25℃室温放置1个月后其平均粒径为144.7±2.8nm,其粒径变化无明显差异,显示其稳定性良好。1.0g of astaxanthin solid self-microemulsion system was added to 100g of deionized water, and after uniform dispersion, the average particle size of astaxanthin solid self-microemulsion system after water dispersion was measured by particle size analyzer was 137.5±3.3nm, and the temperature was 25°C. After being placed at room temperature for 1 month, the average particle size was 144.7±2.8 nm, and there was no significant difference in the particle size change, indicating good stability.
实施例3:Example 3:
称取0.5 g虾青素以及7.5g辛癸酸甘油三酯,将虾青素、辛癸酸甘油三酯混合后于室温下搅拌至大部分虾青素溶解到辛癸酸甘油三酯中,形成体系的油相;称取5.0g十聚甘油单月桂酸酯和2.5g鲸蜡基聚乙二醇/聚丙二醇-10/1二甲基硅氧烷,将十聚甘油单月桂酸酯和鲸蜡基聚乙二醇/聚丙二醇-10/1二甲基硅氧烷于50℃恒温水浴中搅拌加入油相中,使其充分混合形成均一相,得到虾青素液态自微乳;冷却至常温后,向虾青素液态自微乳中加入20g的无水磷酸氢钙作为固体吸附剂,在常温下进行物理混合吸附,使其混合均匀,最终得到虾青素固体自微乳。Weigh 0.5 g of astaxanthin and 7.5 g of caprylic capric triglyceride, mix astaxanthin and caprylic capric triglyceride and stir at room temperature until most of the astaxanthin is dissolved in caprylic capric triglyceride, Form the oil phase of the system; weigh 5.0 g of decaglycerol monolaurate and 2.5 g of cetyl polyethylene glycol/polypropylene glycol-10/1 dimethylsiloxane, decaglycerol monolaurate and Cetyl polyethylene glycol/polypropylene glycol-10/1 dimethyl siloxane was added to the oil phase with stirring in a constant temperature water bath at 50°C to make it fully mixed to form a homogeneous phase to obtain astaxanthin liquid self-microemulsion; cooling After reaching normal temperature, add 20 g of anhydrous calcium hydrogen phosphate to the astaxanthin liquid self-microemulsion as a solid adsorbent, and carry out physical mixing and adsorption at normal temperature to make it mix evenly, and finally obtain astaxanthin solid self-microemulsion.
将1.0 g虾青素固体自微乳体系加入到100g去离子水中,均匀分散后,利用粒度仪测得虾青素固体自微乳体系水分散后平均粒径为105.2±1.9nm,并25℃室温放置1个月后其平均粒径为110.5±1.0 nm,其粒径变化无明显差异,显示其稳定性良好。1.0 g of astaxanthin solid self-microemulsion system was added to 100g of deionized water, and after uniform dispersion, the average particle size of astaxanthin solid self-microemulsion system after water dispersion was measured by particle size analyzer was 105.2±1.9nm, and the temperature was 25 ℃. After being placed at room temperature for 1 month, the average particle size was 110.5±1.0 nm, and there was no significant difference in particle size change, indicating good stability.
上述实例只为说明本发明的技术构思及特点,其目的在于让本领域专业技术人员能够了解本发明的内容并据以实施,并不能以此限制本发明的保护范围。凡根据本发明精神实质所做的改变、修饰、替代、组合、简化,均应为等效的置换方式,都包含在本发明的保护范围之内。The above examples are only to illustrate the technical concept and characteristics of the present invention, and the purpose thereof is to enable those skilled in the art to understand the content of the present invention and implement accordingly, and cannot limit the protection scope of the present invention. All changes, modifications, substitutions, combinations, and simplifications made according to the spirit of the present invention should be equivalent substitution methods, and are included in the protection scope of the present invention.
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910357578.5A CN109985008A (en) | 2019-04-29 | 2019-04-29 | A kind of astaxanthin solid self-microemulsion and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910357578.5A CN109985008A (en) | 2019-04-29 | 2019-04-29 | A kind of astaxanthin solid self-microemulsion and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109985008A true CN109985008A (en) | 2019-07-09 |
Family
ID=67135599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910357578.5A Pending CN109985008A (en) | 2019-04-29 | 2019-04-29 | A kind of astaxanthin solid self-microemulsion and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109985008A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111264860A (en) * | 2020-01-19 | 2020-06-12 | 上海海洋大学 | Solid self-microemulsion microcapsules containing astaxanthin and quercetin and preparation method and application thereof |
CN112353704A (en) * | 2020-11-20 | 2021-02-12 | 苏州纳康生物科技有限公司 | Preparation method of paeonol nano lipid particle |
CN113081870A (en) * | 2019-12-23 | 2021-07-09 | 嘉兴睿肤丽生物科技有限公司 | Preparation method of astaxanthin nano-liposome and application of astaxanthin nano-liposome in cosmetics |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100835250B1 (en) * | 2006-09-07 | 2008-06-09 | 주식회사 바이오랜드 | Self-emulsifying carrier and its manufacturing method |
CN101301282A (en) * | 2008-07-09 | 2008-11-12 | 厦门大学 | Astaxanthin self-emulsifying soft capsule preparation and preparation method thereof |
CN104324020A (en) * | 2014-11-06 | 2015-02-04 | 江苏隆力奇生物科技股份有限公司 | Preparation method of astaxanthin and resveratrol-containing self-microemulsion particles |
CN104473878A (en) * | 2014-11-20 | 2015-04-01 | 中国海洋大学 | Method for preparing high-aqueous-dispersion astaxanthin ester microspheres |
CN105188670A (en) * | 2013-03-15 | 2015-12-23 | 微分药物发展联合有限公司 | Emulsion formulations |
CN107242999A (en) * | 2017-05-04 | 2017-10-13 | 方达医药技术(苏州)有限公司 | A kind of multiple self-emulsifying carrier of solid and preparation method thereof |
-
2019
- 2019-04-29 CN CN201910357578.5A patent/CN109985008A/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100835250B1 (en) * | 2006-09-07 | 2008-06-09 | 주식회사 바이오랜드 | Self-emulsifying carrier and its manufacturing method |
CN101301282A (en) * | 2008-07-09 | 2008-11-12 | 厦门大学 | Astaxanthin self-emulsifying soft capsule preparation and preparation method thereof |
CN105188670A (en) * | 2013-03-15 | 2015-12-23 | 微分药物发展联合有限公司 | Emulsion formulations |
CN104324020A (en) * | 2014-11-06 | 2015-02-04 | 江苏隆力奇生物科技股份有限公司 | Preparation method of astaxanthin and resveratrol-containing self-microemulsion particles |
CN104324020B (en) * | 2014-11-06 | 2016-09-21 | 江苏隆力奇生物科技股份有限公司 | A kind of self-microemulsion preparation method of granules containing astaxanthin Yu resveratrol |
CN104473878A (en) * | 2014-11-20 | 2015-04-01 | 中国海洋大学 | Method for preparing high-aqueous-dispersion astaxanthin ester microspheres |
CN107242999A (en) * | 2017-05-04 | 2017-10-13 | 方达医药技术(苏州)有限公司 | A kind of multiple self-emulsifying carrier of solid and preparation method thereof |
Non-Patent Citations (2)
Title |
---|
MAO, XINYU等: "Development of a Solid Self-Emulsification Delivery System for the Oral Delivery of Astaxanthin", 《EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY》 * |
孙娟娟等: "固体自微乳载体、固体化方法及稳定性研究进展", 《中国医院药学杂志》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113081870A (en) * | 2019-12-23 | 2021-07-09 | 嘉兴睿肤丽生物科技有限公司 | Preparation method of astaxanthin nano-liposome and application of astaxanthin nano-liposome in cosmetics |
CN111264860A (en) * | 2020-01-19 | 2020-06-12 | 上海海洋大学 | Solid self-microemulsion microcapsules containing astaxanthin and quercetin and preparation method and application thereof |
CN112353704A (en) * | 2020-11-20 | 2021-02-12 | 苏州纳康生物科技有限公司 | Preparation method of paeonol nano lipid particle |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hadian et al. | Preparation and characterization of nanoparticle β-cyclodextrin: Geraniol inclusion complexes | |
CN105287666B (en) | A kind of preparation method of Seabuckthorm Seed Oil | |
CN109985008A (en) | A kind of astaxanthin solid self-microemulsion and preparation method thereof | |
CA2701605A1 (en) | Granule, tablet and methods for producing the same | |
JP2009524576A (en) | Nano-sized carotenoid / cyclodextrin complex | |
DE102010015143A1 (en) | Stable liquid oily ready-to-use formulations, preparation thereof and use thereof | |
CN106455667A (en) | Formulation of fat-soluble vitamin | |
KR101521868B1 (en) | Preparation and stabilization of idebenone encapsulated with skin lipids complex and moisturizing oil and its application of anti-aging cosmetics | |
CN101744288B (en) | Clear oral preparation with coenzyme Q10 and preparation method thereof | |
EP3223630A1 (en) | Stable oil suspensions comprising lipophilic nutrient with enhanced bioavailability and process of preparation | |
WO2022222683A1 (en) | Coenzyme q10 microemulsion, preparation method therefor and use thereof | |
CN102973528B (en) | Calcitriol solid lipidic dispersion and preparation method thereof | |
KR101910694B1 (en) | Iron supplement composition | |
CN103251572B (en) | Preparation method of theaflavin enteric microcapsule, as well as product prepared by preparation method and application of product | |
KR102291310B1 (en) | Solid compositions of triglycerides and uses thereof | |
CN104523606B (en) | The method that self-assembly method prepares gossypol and its derivative pluronic nano-particle | |
CN102511821B (en) | Composite lipid-lowering soft capsule preparation prepared by lycopene and grapestone extracts and preparation method of composite lipid-lowering soft capsule preparation | |
CN107897647B (en) | A kind of green preparation method of water-soluble lutein | |
CN109924491A (en) | A kind of dihydromyricetin solid-state self-emulsifying material and its preparation method and application | |
CN105193844A (en) | Method for preparing delta-hydroxyl contained ferric oxide (multinuclear) and medicine compositions of delta-hydroxyl contained ferric oxide, as well as application to field of hyperphosphatemia | |
CN101772352B (en) | Liquid composition for soft capsule filling | |
CN115634198A (en) | Solvent composition for water-insoluble substances and preparation method and application thereof | |
CN107536808B (en) | Miriplatin freeze-dried preparation and preparation method thereof | |
CN118750454B (en) | Preparation method and application of vitamin D dry powder raw material wrapped by nano fat emulsion | |
CN116869934B (en) | A supramolecular nanocolloid of polyphenols and its preparation method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190709 |